Mark E. Cleasby

2.8k total citations · 1 hit paper
33 papers, 2.1k citations indexed

About

Mark E. Cleasby is a scholar working on Molecular Biology, Physiology and Rehabilitation. According to data from OpenAlex, Mark E. Cleasby has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 16 papers in Physiology and 5 papers in Rehabilitation. Recurrent topics in Mark E. Cleasby's work include Adipose Tissue and Metabolism (16 papers), Metabolism, Diabetes, and Cancer (11 papers) and Muscle Physiology and Disorders (8 papers). Mark E. Cleasby is often cited by papers focused on Adipose Tissue and Metabolism (16 papers), Metabolism, Diabetes, and Cancer (11 papers) and Muscle Physiology and Disorders (8 papers). Mark E. Cleasby collaborates with scholars based in United Kingdom, Australia and United States. Mark E. Cleasby's co-authors include Philip J. Atherton, Pauline Jamieson, Gregory J. Cooney, Jonathan R. Seckl, Edward W. Kraegen, Moffat Nyirenda, Paul A. Kelly, Ditte K. Andersen, Caroline Wheeler‐Jones and Bronwyn D. Hegarty and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Physiology and Diabetes.

In The Last Decade

Mark E. Cleasby

33 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin resistance and sarcopenia: mechanistic links between common co-morbidities

2016 419 citations Mark E. Cleasby, Pauline Jamieson et al. Journal of Endocrinology profile →

Peers

Countries citing papers authored by Mark E. Cleasby

Since Specialization

Citations

This map shows the geographic impact of Mark E. Cleasby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Cleasby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Cleasby more than expected).

Fields of papers citing papers by Mark E. Cleasby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Cleasby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Cleasby. The network helps show where Mark E. Cleasby may publish in the future.

Co-authorship network of co-authors of Mark E. Cleasby

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Cleasby. A scholar is included among the top collaborators of Mark E. Cleasby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Cleasby. Mark E. Cleasby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of antisense-mediated myostatin knockdown for the treatment of insulin resistance 2021 ·Scientific Reports ·(unknown), Mark E. Cleasby, Keith Foster	8
2	Overexpression of the vitamin D receptor (VDR) induces skeletal muscle hypertrophy 2020 ·Molecular Metabolism ·Joseph J. Bass, (unknown), Colleen S. Deane, Matthew S. Brook, Daniel J. Wilkinson, Bethan E. Phillips, Andrew Philp, (unknown), Fawzi Kadi, Ditte K. Andersen, (unknown), Kenneth Smith, Iain J. Gallagher, Nathaniel J. Szewczyk, Mark E. Cleasby, Philip J. Atherton	73
3	The mechanisms of skeletal muscle atrophy in response to transient knockdown of the vitamin D receptor in vivo 2020 ·The Journal of Physiology ·Joseph J. Bass, Abid A. Kazi, Colleen S. Deane, (unknown), Stephen P. Ashcroft, Matthew S. Brook, Daniel J. Wilkinson, Bethan E. Phillips, Andrew Philp, (unknown), Fawzi Kadi, Ditte K. Andersen, (unknown), Kenneth Smith, Iain J. Gallagher, Nathaniel J. Szewczyk, Mark E. Cleasby, Philip J. Atherton	45
4	A highly prevalent equine glycogen storage disease is explained by constitutive activation of a mutant glycogen synthase 2016 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·(unknown), Janne R. Hingst, (unknown), Andrias O. O’Reilly, Mark E. Cleasby, James R. Mickelson, Molly E. McCue, Susan M. Anderson, Thomas D. Hurley, Jørgen F. P. Wojtaszewski, Richard J. Piercy	15
5	Sclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitus 2016 ·Osteoporosis International ·Marie Pereira, (unknown), (unknown), (unknown), Peter Smitham, Michael Oddy, Ines Reichert, Delphine Farlay, Jean‐Paul Roux, Mark E. Cleasby, Chantal Chenu	24
6	Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells 2015 ·British Journal Of Nutrition ·Luise Heinrich, Ditte K. Andersen, Mark E. Cleasby, Charlotte Lawson	59
7	The RabGAP TBC1D1 Plays a Central Role in Exercise-Regulated Glucose Metabolism in Skeletal Muscle 2015 ·Diabetes ·Jacqueline Stöckli, Christopher C. Meoli, Nolan J. Hoffman, Daniel J. Fazakerley, (unknown), Mark E. Cleasby, Xiuquan Ma, Maximilian Kleinert, Amanda E. Brandon, Jamie Lopez Bernal, Gregory J. Cooney, David E. James	47
8	Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice 2015 ·Bone ·Marie Pereira, Jeshmi Jeyabalan, (unknown), Mark Hopkinson, (unknown), Jean‐Paul Roux, Pascale Chavassieux, Isabel R. Orriss, Mark E. Cleasby, Chantal Chenu	113
9	Loss of neuronatin promotes “browning” of primary mouse adipocytes while reducing Glut1-mediated glucose disposal 2013 ·American Journal of Physiology-Endocrinology and Metabolism ·Valentina Gburcik, Mark E. Cleasby, James A. Timmons	34
10	Saturated fatty acid-activated macrophage-conditioned medium activates MAP kinases and impairs insulin sensitivity in C2C12 myotubes 2012 ·(unknown), Caroline Wheeler‐Jones, Mark E. Cleasby	1
11	The adaptor protein APPL1 increases glycogen accumulation in rat skeletal muscle through activation of the PI3-kinase signalling pathway 2011 ·Journal of Endocrinology ·Mark E. Cleasby, (unknown), (unknown), (unknown), Stephen J Leslie, Nigel Turner, Gregory J. Cooney, (unknown), Edward W. Kraegen	38
12	Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and insulin resistance on a high fat diet 2009 ·Pauline Jamieson, Mark E. Cleasby, Nicholas M. Morton, Paul Kelly, (unknown), David G. Brownstein, Jonathan R. Seckl, Wylie Vale	1
13	Rev-erb beta regulates the Srebp-1c promoter and mRNA expression in skeletal muscle cells 2009 ·Biochemical and Biophysical Research Communications ·(unknown), Patrick Lau, Lisa M. Crowther, Mark E. Cleasby, Susan Millard, Gary M. Leong, Gregory J. Cooney, George E.O. Muscat	15
14	Local activation of the IκK-NF-κB pathway in muscle does not cause insulin resistance 2007 ·American Journal of Physiology-Endocrinology and Metabolism ·(unknown), (unknown), Gregory J. Cooney, Edward W. Kraegen, Mark E. Cleasby	18
15	Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification 2006 ·American Journal of Physiology-Endocrinology and Metabolism ·Clinton R. Bruce, Camilla Brolin, Nigel Turner, Mark E. Cleasby, Feike R. van der Leij, Gregory J. Cooney, Edward W. Kraegen	57
16	Functional Studies of Akt Isoform Specificity in Skeletal Muscle in Vivo; Maintained Insulin Sensitivity Despite Reduced Insulin Receptor Substrate-1 Expression 2006 ·Molecular Endocrinology ·Mark E. Cleasby, (unknown), Gregory J. Cooney, David E. James, Edward W. Kraegen	87
17	Nur77 Regulates Lipolysis in Skeletal Muscle Cells 2005 ·Journal of Biological Chemistry ·Megan Maxwell, Mark E. Cleasby, Angus Harding, Annika Stark, Gregory J. Cooney, George E.O. Muscat	140
18	Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin 2004 ·Diabetologia ·(unknown), Nicolas Dzamko, Mark E. Cleasby, Bronwyn D. Hegarty, Stuart M. Furler, Gregory J. Cooney, Edward W. Kraegen	108
19	Programming of Rat Muscle and Fat Metabolism by in Utero Overexposure to Glucocorticoids 2003 ·Endocrinology ·Mark E. Cleasby, Paul A. Kelly, Brian R. Walker, Jonathan R. Seckl	104
20	Glucocorticoids, 11β-hydroxysteroid dehydrogenase, and fetal programming 2000 ·Kidney International ·Jonathan R. Seckl, Mark E. Cleasby, Moffat Nyirenda	186

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact